



**Program Announcement for the Defense Health Agency**

# **Duchenne Muscular Dystrophy Research Program Idea Development Award**

Funding Opportunity Number: HT942526DMDRPIDA

Pre-Application Due: September 4, 2026

Application Due: September 18, 2026

*This program announcement must be read in conjunction with the General Application Instructions, version [CD26\\_01](#).*

# Content

	<b>Before You Begin</b>	<b>3</b>
①	<b>Basic Information</b> Summarizes the <u>funding opportunity</u> , <u>funding details</u> , <u>submission deadlines and review dates</u>	<b>4</b>
②	<b>Eligibility</b> Details eligibility factors for the <u>applicant organization</u> and <u>Principal Investigator</u>	<b>5</b>
③	<b>Program Description</b> Describes the <u>program mission</u> and <u>intent of the Idea Development Award</u> ; provides <u>key award information</u> and <u>considerations</u> ; and outlines <u>funding details</u>	<b>6</b>
④	<b>Application Contents</b> Presents the two-step <u>application process</u> and instructions for preparing a <u>pre-application</u> and <u>full application</u>	<b>10</b>
⑤	<b>Submission Requirements</b> Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	<b>17</b>
⑥	<b>Application Review Information</b> Outlines the processes for application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also, details the review criteria for <u>pre-application screening</u> and both tiers of the CDMRP application review process – <u>Peer Review</u> and <u>Programmatic Review</u>	<b>19</b>
⑦	<b>Federal Award Notices</b> Outlines what a successful applicant can expect <u>if recommended for funding</u>	<b>23</b>
⑧	<b>Post-Award Requirements</b> References <u>policy requirements</u> for funded research; outlines <u>reporting requirements</u> and restrictions related to <u>Principal Investigator changes</u> and <u>institutional award transfers</u>	<b>24</b>
⑨	<b>Other Information</b> Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	<b>26</b>
	<b>Appendix 1</b> Includes a checklist for all full application components to facilitate application submission	<b>28</b>
	<b>Appendix 2</b> Acronym List	<b>29</b>

## Before You Begin

- **Active [SAM.gov](#), [eBRAP.org](#) and [Grants.gov](#) registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process [FAQ](#), a [Guide for Intragovernmental & Intramural Applicants](#) and a [CDMRP Video Series](#) detailing the application process.

## Who to Contact for Support

### eBRAP Help Desk

301-682-5507  
[help@eBRAP.org](mailto:help@eBRAP.org)

*Questions regarding  
funding opportunity submission  
requirements,  
as well as technical assistance  
related to pre-application or  
intramural application submission.*

### Grants.gov Support Center

800-518-4726  
International: 1-606-545-5035  
[support@grants.gov](mailto:support@grants.gov)

*Questions regarding  
Grants.gov registration  
and Workspace.*

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click  to be taken to additional guidance and instructions within the General Application Instructions (GAI).

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

# 1. Basic Information About the Funding Opportunity

**Summary:** The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. ***The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.***

**Distinctive Features:** The FY26 DMDRP IDA mechanism offers three eligibility career categories:

- The Established Investigator category is for independent investigators at all academic levels, or equivalent
- The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.
- The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.

Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are **required** for all applications. Clinical trials or clinical trial aims are not allowed.

**Funding Details:** The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly **\$2.5M** to fund approximately 5 Idea Development Award applications with total cost caps of **\$500,000** per award. The maximum period of performance is **2** years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

### **Submission and Review Dates and Times**

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), September 4, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 18, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, September 25, 2026
- **Peer Review:** December 2026
- **Programmatic Review:** February 2027

**Announcement Type:** Initial

**Funding Opportunity Number:** HT942526DMDRPIDA

**Assistance Listing Number:** 12.420

## Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## 2. Eligibility Information

### 2.1. Eligible Applicants

#### 2.1.1. Organization

[Extramural](#) and [intramural U.S. Department of War \(DOW\)](#) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

#### 2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status.

Only one PI career category may be chosen; the choice of application category is at the PI's discretion, provided the eligibility criteria are met.

- **Established Investigator**

- The PI must be an independent investigator at all academic levels, or equivalent.

- **New Investigator – Early Stage**

By the application submission deadline date, the PI must:

- Be an independent investigator, or equivalent, who is within 10 years of their first faculty appointment, or equivalent, by the time of the application submission deadline. Applicants may articulate lapses in research time or appointments denoted in the biographical sketch, in the application.
- Not have previously received a Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA).

- **New Investigator – Transitioning**

By the application submission deadline date, the PI must:

- Be an independent investigator at all academic levels, or equivalent, in an area other than muscular dystrophy who is seeking to transition to a career in Duchenne muscular dystrophy (DMD), thereby bringing their expertise to the field.
- Investigators must pursue an active line of research in DMD and commit at least 10% minimum effort during each budget year toward the proposed DMD research project.

### 2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

### 2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional [recipient qualification requirements](#).

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Duchenne Muscular Dystrophy Research Program (DMDRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the DMDRP in 2011 to provide support for research of high potential impact and exceptional scientific merit. Appropriations for the DMDRP from FY11 through FY25 totaled \$92.1 million (M). The FY26 appropriation is \$12.5M.

The vision of the FY26 DMDRP is to preserve and improve the function and quality of life across the lifespan of all individuals with DMD. As such, the DMDRP seeks to support discovery, development, and delivery of safe, effective therapeutics for DMD at all stages of the disease for the benefit of military Families and the general public. Additionally, the DMDRP supports the efforts of the National Institutes of Health (NIH) Muscular Dystrophy Coordinating Committee (MDCC) and the [2015 MDCC Action Plan for the Muscular Dystrophies](#), which prioritizes the need to improve treatments and reduce the disease burden for muscular dystrophies, including DMD.

***The DMDRP seeks to support research that is relevant to the health care needs of Service Members, Veterans, and their Families, and/or Family readiness of Service Members. Musculoskeletal injuries and diseases are the third leading cause of medical encounters for active Service Members. Drug repurposing and development of novel advanced technologies to improve muscle strength and function after injury and disease are relevant to the support of Warfighter readiness and lethality. Additional information on relevance to military health can be found on the [Program Summary Sheet](#) on the [DMDRP website](#).***

#### 3.1. Intent of the Idea Development Award

The FY26 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.

***Applications must include preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches. Preliminary data may include unpublished results from the laboratory of the PI, research team, or collaborators named on the application.***

##### 3.1.1. Focus Area for the IDA

To meet the intent of the funding opportunity, ***applications must address opportunities and challenges in the development of safe and effective therapies that focus on primary pathology of DMD.*** Therapies that will be efficacious for patients across the lifespan, including infants, toddlers and non-ambulatory individuals, are strongly encouraged.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Studies proposed under this award mechanism *may* include:

- Research that will inform and improve therapy in individuals ineligible for currently approved therapies or in-development therapeutics (e.g., due to age, type of mutations, seropositivity, rare exons).
- Optimizing non-adenoviral-associated virus (AAV) or non-viral delivery to specific tissues or cell types, including targeting to skeletal muscle, heart, brain and muscle stem cells (e.g., ligand-assisted delivery, tissue-specific promoters, nanoparticles, alternative vectors, identification of biological barriers to delivery).
- Therapies that address muscle regeneration deficits.
- Strategies to overcome preexisting immunity and to facilitate repeat administration of biologic therapies (e.g., immune system modulation, vector modification).
- Repopulation of the muscle compartment using cell-based therapies, including, but not limited to, selection of novel cell types, expansion, cell delivery and homing, differentiation and integration.
- Non-genomic therapies that are downstream from the genetic defect to address disease pathogenesis (e.g., inflammation, fibrosis, fatty infiltration, mitochondrial dysfunction, etc.).
- Preclinical testing of therapies in combination with standard of care treatments or approved products.
- Discovery and validation of novel targets, including genetic modifiers and factors that determine the selective vulnerability/resistance of individual muscles, especially in humans.
- Validation of novel models to address human pathophysiology in DMD beyond skeletal muscle (e.g., smooth muscle, CNS).
- Identification of novel, minimally invasive biomarkers that allow evaluation of therapeutic effectiveness with strong potential for clinical translatability.

Studies in the following research areas will *not* be supported by this award mechanism:

- Testing the efficacy of candidate therapeutics without a strong mechanistic rationale.
- Evaluation of vectors or delivery technologies already prevalent in research studies (e.g., AAV9).

### 3.1.2. Key Elements for the IDA

- **Impact:** Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.

***The applicant should articulate the project's near-term impact to both DMD research and individuals with DMD, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack high potential impact do not meet the intent of the IDA.***

***New Investigators:*** In addition to established DMD investigators, the FY26 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) ***and*** applications from established investigators new to DMD research.

- The New Investigator – Early Stage category is designed to allow independent investigators early in their faculty appointments to be reviewed separately from established investigators.

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

- The [New Investigator – Transitioning](#) category is designed to allow independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applications in this category will be reviewed separately from established DMD investigators.

The DMDRP strongly encourages PIs using the New Investigator – Early Stage category or New Investigator – Transitioning category to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI's expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in [Section 2, Eligibility Information](#).

### 3.1.3. Other Important Considerations for the IDA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, the CDMRP does **not** support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

**[Clinical trials](#) are not allowed within this funding opportunity; however, research involving human subjects and human anatomical substances is permitted.**

Investigators wishing to apply for funding to support a clinical trial should consider submitting an application to the FY26 DMDRP Clinical/Translational Research Award, funding opportunity number HT942526DMDRPCTRA.

***For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from [clinical research](#).***

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the [STROBE](#), [CONSORT](#), [SPIRIT](#) and [ARRIVE 2.0](#) guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

## 3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

## 3.3. Funding Details

**[Period of Performance](#):** The maximum period of performance is **2** years.

**[Cost Cap](#):** The application's total costs budgeted for the entire period of performance should not exceed **\$500,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **2** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

**Direct Cost Restrictions:** For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Costs for **one** investigator to travel to **one** scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 DMDRP IDA.

Must not be requested for:

- Clinical trial costs.
- Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 4. Application Contents and Format

## 4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

**Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.**



**Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.**



## 4.2. Pre-Application Components

Pre-application submissions must include the following components.

**Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted.

LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review. **An invitation to submit a full application is NOT provided after LOI submission. Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.**

## 4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

**(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):**



***IMPORTANT:*** When completing the SF424 R&R, enter the **eBRAP log number** assigned during pre-application submission into **Block 4a – Federal Identifier**.

**(b) Attachments:**

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the [formatting guidelines](#) in the GAI.

- **Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”.**



Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and reasoning behind the proposed research. The application must provide a sound scientific rationale to support the proposed project and its feasibility as established through the demonstration of logical reasoning and critical review and analysis of published literature; include relevant literature citations. Include preliminary data to support the scientific rationale and feasibility of the research approaches. Applications are strongly encouraged to also include preliminary data to support the clinical relevance of the idea. Any unpublished

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- preliminary data provided should originate from the laboratory of the PI(s) or a member(s) of the research team.
- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
  - **Specific Aims:** Concisely explain the project's specific aims to be supported by this application. If the proposed research is part of a larger study, present only tasks that this award would fund.
  - **Research Strategy and Feasibility:** Describe the experimental design, methods, and analyses including appropriate controls, in sufficient detail for evaluation. Clearly describe how data will be collected and analyzed in a manner that is consistent with the study objectives. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Address potential limitations and present alternative methods and approaches. Describe availability of, access to, and quality control for all data and/or critical reagents, and/or cohorts, where relevant.
    - If animal studies are proposed, describe how they will be conducted in accordance with the [ARRIVE guidelines 2.0](#) to achieve reproducible and rigorous results, including the choice of model and the endpoint/outcomes to be measured.
    - If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples.
    - For clinical research, describe the strategy for the inclusion of women and minorities in the clinical research appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, race, and/or ethnicity, and an accompanying rationale for the selection of subjects. ***This award cannot be used to support clinical trials.***
    - If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the General Application Instructions, [Appendix 4](#), for additional considerations.
  - **Statistical Analysis Plan:** Describe the statistical analysis plan for the resulting outcomes. If applicable, include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA), if applicable.
  - **Statement of Collaboration (optional; encouraged for applications submitting to a New Investigator eligibility criterion):** Describe the composition of the study team, partners, or any collaborations in enough detail to determine whether the team includes relevant DMD subject matter or other relevant expertise to accomplish the proposed work as it relates to the study hypothesis or objective. Describe how the collaboration will augment the PI's expertise to best address the research question.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.**



*There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.*

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).
- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support (two-page limit per letter is recommended):** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI’s Department Chair, or appropriate organization official, should also confirm that the PI(s) meet [eligibility criteria](#). If applicable, provide a letter of support signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Data and/or Research Sharing Plan:** Describe the type of data and/or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

***Do not submit a copy of the NIH Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.***

Refer to the [CDMRP Directive on Sharing Data and Research Resources](#) for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Inclusion Enrollment Report (*only required if clinical research is proposed*):** Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the "[Public Health Service \(PHS\) Inclusion Enrollment Report](#)", a three-page fillable PDF form that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf"**. 

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
- **Hypothesis/Objective(s):** State the hypothesis to be tested and/or objective(s) to be reached. Provide evidence or scientific rationale that supports the hypothesis/objective(s).
- **Specific Aims:** State the specific aims of the study, ensuring they address opportunities and challenges in the development of safe and effective therapies that focus on primary pathology of DMD.
- **Study Design:** Describe the study design, including appropriate controls.
- **Impact:** Describe how the proposed project may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.
- **Military Relevance:** Describe how the study is relevant to military health.


- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf"**. 

The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine***. Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

- Summarize the objectives and rationale for the proposed research.
- What population will the research help, and how will it help them?
- What are the potential applications, benefits and risks of the anticipated outcomes?

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- What are the likely contributions of the proposed research project to advancing DMD research, patient care and/or quality of life?
- What is the projected time anticipated to achieve a clinically relevant outcome?
- What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.**   
Refer to eBRAP for the [Suggested SOW Format](#).

For guidance on preparing the SOW, refer to the [Example: Assembling a Generic Statement of Work](#). Include milestones for data or research resource(s) sharing.



- **Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”.** *The Impact Statement should be written in plain language with a broad audience in mind, including readers without a background in science or medicine. The Impact Statement should articulate the project’s near-term impact to both DMD research and to individuals with DMD, even if clinical impact is not an immediate outcome.*
  - Describe how the proposed project is expected to make an important and original contribution to addressing opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. **The relevance of all research, including basic, should relate to patient outcomes and how it benefits those affected by DMD.**
  - Explain how the proposed research will significantly accelerate progress towards improving outcomes for individuals with DMD.
  - Explain briefly how the proposed research is relevant to the health care needs of Service Members, Veterans, their Families, and/or Family readiness of Service Members.
- **Attachment 7: Research Outcomes Plan: (one-page limit): Upload as “Outcomes.pdf”.**
  - Describe the anticipated research outcomes, including knowledge products, clinical products for development, etc.
  - Describe the methods and strategies proposed to move the anticipated research outcomes to the next phase of development or clinical application after successful completion of the project.
  - Detail the funding strategy to transition to the next level of investigation, development, and/or commercialization (e.g., partners, internal/external funding opportunities to be applied for).
  - Demonstrate that a plan for management of intellectual property is in place.
- **Attachment 8: Animal Research Plan (five-page limit): Upload as “AnimalResPlan.pdf”.** *(Attachment 8 is only applicable and required for applications proposing animal studies.)*

If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. Consult the [ARRIVE guidelines 2.0](#) (Animal Research: Reporting *In Vivo* Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Institutional Animal Care and Use Committee (IACUC). The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:

- Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology.
  - Summarize the procedures to be conducted. Describe how the study will be controlled.
  - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
  - Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 9: Representations (*Grants.gov submissions only*): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [Required Representations](#) document available on eBRAP. 
  - **Attachment 10: Suggested Intragovernmental/Intramural Budget Form (*if applicable*): Upload as “IGBudget.pdf”.** If an [intramural DOW organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [Suggested Intragovernmental/Intramural Budget](#) form available on eBRAP. 

### (c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.



Grants.gov



eBRAP.org

---

#### i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**
- **Current/Pending Support**

*Intragovernmental applicants must include their internally supported research and development programs.*

---

#### ii. Research & Related Budget

---

#### iii. Project/Performance Site Location(s)

---

#### iv. Research & Related Subaward Budget Attachment(s) (*if applicable, Grants.gov submissions only*)

---

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instructions 3200.12](#) will be requested.



The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 5. Submission Requirements

## 5.1. Location of Application Package

Download the application package components for HT942526 DMDRPIDA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


## 5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. i

## 5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

### *Application Submission Workflow*



### 5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through [eBRAP](#). i

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire

## Section Shortcuts


Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the [eBRAP Help Desk](#) if any changes need to be made.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:


Application Includes:	Select Mechanism Option:
Established Investigator	Idea Development Award – Established Investigator
New Investigator – Early Stage	Idea Development Award – New Investigator – Early Stage
New Investigator – Transitioning	Idea Development Award – New Investigator – Transitioning

### 5.3.2. Full Application Submission

**Grants.gov Submissions:** Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. 

**eBRAP Submissions:** Only [intramural DOW organizations](#) may submit full applications through eBRAP. 

### 5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission.   
***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the [application verification period](#) ends. The full application cannot be modified once the application verification period ends.

### 5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in [Section 1, Basic Information](#).

### 5.5. Intergovernmental Review

Not applicable for this funding opportunity.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

# 6. Application Review Information

## 6.1. Application Compliance Review

***Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).***

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's Directive on Research Duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.



Members of the FY26 DMDRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the [FY26 DMDRP Programmatic Panel members can be found on the CDMRP website.](#)***

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

## 6.2. Review Criteria

### 6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

### 6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, with impact ranking as the most important:

- **Impact**
  - How well the proposed research addresses opportunities and challenges in the development of safe and effective therapies that address primary pathology of DMD.
  - To what degree the proposed will significantly accelerate progress towards improving outcomes for individuals with DMD.
- **Research Strategy and Feasibility**
  - How well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
**Application Review Information** | Federal Award Notices | Post-Award Requirements | Other Information

- How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, relevant preliminary data, and logical reasoning.
- How well the hypotheses or objectives, aims, experimental design, methods, analyses, data collection, statistical analysis plan, rationale for the statistical methodology, and power analysis (if applicable) are developed.
- If animal studies are included, how well studies are designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured.
- If human subjects or human biological samples will be used, how well the plan for the recruitment of subjects or the acquisition of samples is justified and appropriate to accomplish the proposed work.
- How well the SOW indicates a feasible plan and timeline to conduct the research and provides clearly defined research milestones to be accomplished by the end of each year in the period of performance.
- Whether there is documented availability of, access to, and quality control for all data and/or critical reagents, and/or cohorts, where relevant.
- How well the application acknowledges potential limitations and addresses alternative methods and approaches.
- If applicable, whether data will be appropriately reported and documented to support a regulatory filing with the FDA.
- **Personnel**
  - The degree to which the levels of effort by the applicant (minimum of 10% for New Investigators – Transitioning per budget year) and other key personnel are appropriate to ensure the success of this research effort.
  - How appropriate the expertise are for successful conduct of the proposed work.
  - For New Investigators – Transitioning, to what extent the PI will bring their expertise to the field of DMD and pursue an active line of research in DMD.
- **Research Outcomes**
  - How well the application demonstrates feasible methods and strategies to move the anticipated research outcomes to the next phase of development, clinical trials, and/or delivery to the commercial market after successful completion of the award.
  - Whether the proposed transition plan includes sufficient evidence that the PI has or can secure additional funding, or whether the plan clearly describes potential options to secure the additional funding needed to bring the outcomes to the next phase of development.
  - Whether the plan for management of intellectual property is appropriate and feasible.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
  - Whether the proposed plan for data and/or research sharing includes databases most relevant to DMD (if applicable), and whether the plan describes organizational and

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

technical capabilities sufficient to share project data in a timely manner. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.

- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

### 6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 DMDRP, as evidenced by the following:
  - Adherence to the intent of the funding opportunity
  - Program portfolio composition
  - Impact and relevance to military health

## 6.3. Application Review and Selection Process

### 6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. ***CDMRP will NOT provide an invitation to submit a full application after pre-application submission.*** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

### 6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various***

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

*factors as described in [Section 6.2.3, Programmatic Review](#).* Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

### 6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information


## 7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the DMDRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable [database](#).

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

***Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization.*** No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

***Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.***

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official. 

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

# 8. Post-Award Requirements


## 8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contain information regarding [administrative requirements](#) and [national policy requirements](#).

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [DHACA Terms and Conditions](#) for further information.

***If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.***

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local IACUC, IRB or Ethics Committee (EC) review. 

## 8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

For all awards including prospective accrual of human subjects, quarterly technical progress reports may be required.

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

An [Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

PHS Inclusion Enrollment Reporting (***required for research proposing clinical research and/or clinical trials***): Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to the SAM about certain civil, criminal and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable [Representations](#).

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

### 8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.



An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

# 9. Other Information

## 9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26\_01d.

## 9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

### 9.2.1. Rejection

The following will result in administrative rejection of the full application:

- Pre-application was not submitted.
- The Project Narrative is missing.
- The Budget is missing.

### 9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

### 9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 DMDRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization):  
(a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.
- The application fails to conform to this program announcement description.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and fiscal year.
- The PI does not meet the [eligibility criteria](#).
- The Animal Research Plan (**Attachment 8**) is missing, for applications proposing animal studies.
- A clinical trial is proposed.

### 9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded
<b>SF424 Research &amp; Related Application for Federal Assistance</b> <i>(Grants.gov submissions only)</i>	<input type="checkbox"/>
<b>Summary (Tab 1) and Application Contacts (Tab 2)</b> <i>(eBRAP submissions only)</i>	<input type="checkbox"/>
<b>Attachments</b>	
<a href="#">Project Narrative</a> – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>
<a href="#">Supporting Documentation</a> – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>
<a href="#">Technical Abstract</a> – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>
<a href="#">Lay Abstract</a> – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>
<a href="#">Statement of Work</a> – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>
<a href="#">Impact Statement</a> – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>
<a href="#">Research Outcomes Plan</a> – Attachment 7, upload as “Outcomes.pdf”	<input type="checkbox"/>
<a href="#">Animal Research Plan</a> – Attachment 8, upload as “AnimalResPlan.pdf”	<input type="checkbox"/>
<a href="#">Representations</a> <i>(Grants.gov submissions only)</i> – Attachment 9, upload as “RequiredReps.pdf”	<input type="checkbox"/>
<a href="#">Suggested Intragovernmental/Intramural Budget Form</a> <i>(if applicable)</i> – Attachment 10, upload as “IGBudget.pdf”	<input type="checkbox"/>
<b><a href="#">Additional Application Materials</a></b>	
<b>Research &amp; Related Senior/Key Person Profile (Expanded)</b>	<input type="checkbox"/>
<b>Attach Biographical Sketch for Senior/Key Persons</b> <b>(Biosketch_LastName.pdf)</b>	<input type="checkbox"/>
<b>Attach Current/Pending Support for Senior/Key Persons</b> <b>(Support_LastName.pdf)</b>	<input type="checkbox"/>
<b>Research &amp; Related Budget</b>	<input type="checkbox"/>
<b>Project/Performance Site Location(s)</b>	<input type="checkbox"/>
<b>Research &amp; Related Subaward Budget Attachment(s)</b> <i>(if applicable)</i>	<input type="checkbox"/>

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

## Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DMDRP	Duchenne Muscular Dystrophy Research Program
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	U.S. Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
IACUC	Institutional Animal Care and Use Committee
IDA	Idea Development Award
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials

### Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs